A. Siefker-Radtke

D. McConkey, B. McGregor, A. Siefker-Radtke, 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition

A. Siefker-Radtke, B. Curti, 2018, Nature Reviews Urology.

p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers

C. Dinney, Yu Shen, D. McConkey, 2012, PloS one.

Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes

F. Meric-Bernstam, Jianjun Gao, A. Naing, 2020, Molecular Cancer Research.

A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC).

E. Jonasch, E. Heath, C. Logothetis, 2015 .

1240: Prospective Evidence Supporting the Utility of Neooadjuvant Chemotherapy in Small Cell Urothelial Cancer: Preliminary Results from A Phase II Clinical Trial at the M.D. Anderson Cancer Center

R. Millikan, C. Dinney, A. Kamat, 2006 .

705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)

J. Christensen, J. Rosenberg, D. Shaffer, 2020 .

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.

P. Ascierto, B. Mellado, P. Sharma, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

S. Boorjian, N. Agarwal, Sam S. Chang, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

p63 expression correlates with sensitivity to the Eg5 inhibitor AZD4877 in bladder cancer cells

C. Dinney, D. McConkey, A. Siefker-Radtke, 2012, Cancer biology & therapy.

Micropapillary bladder cancer

P. Tamboli, C. Dinney, A. Kamat, 2007, Cancer.

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.

Anthony Patterson, Mark K Buyyounouski, Khurshid A Guru, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

The role of radical cystectomy in patients with clinical T4b bladder cancer.

C. Dinney, M. Munsell, A. Kamat, 2011, Urologic oncology.

Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma.

P. Thall, E. Jonasch, C. Ng, 2006, Cancer.

Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses

M. Galsky, P. Sharma, E. Kikuchi, 2019, International Journal of Clinical Oncology.

Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.

R. Huddart, B. Mellado, S. Park, 2023, European urology open science.

Outcomes of Patients with Advanced Urothelial Carcinoma after Anti–programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study

A. Santiago-Walker, D. Papantoniou, A. Necchi, 2022, European urology open science.

Erdafitinib for locally advanced or metastatic urothelial carcinoma

A. Siefker-Radtke, Y. Loriot, 2022, American Journal of Health-System Pharmacy.

Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma.

Jianjun Gao, A. Siefker-Radtke, Alexander Y. Andreev-Drakhlin, 2020, European Urology.

Emerging treatments in advanced urothelial cancer.

Jianjun Gao, A. Siefker-Radtke, M. Campbell, 2020, Current Opinion in Oncology.

Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma

V. Margulis, E. Jonasch, C. Wood, 2014, Cancer.

Bladder cancer, version 3.2020

S. Boorjian, N. Agarwal, Sam S. Chang, 2020 .

LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study

T. Powles, A. Santiago-Walker, T. Kang, 2021, Annals of Oncology.

Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.

Jun Zhu, E. Plimack, W. Oh, 2019, European urology.

Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC).

Jun Zhu, M. Galsky, P. Sharma, 2018 .

Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy

C. Dinney, Jianjun Gao, A. Kamat, 2021, The Journal of urology.

Hyperphosphatemia due to erdafitinib (a pan-FGFR Inhibitor) and anti-tumour activity among patients (Pts) with advanced urothelial carcinoma (UC)

A. Siefker-Radtke, Y. Loriot, S. Tagawa, 2019, Annals of Oncology.

Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.

R. Huddart, B. Mellado, S. Park, 2018 .

FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations.

T. Powles, C. Sternberg, S. Braun, 2020 .

Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22

G. Curigliano, A. Siefker-Radtke, W. Kelly, 2019, Annals of Oncology.

Erdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study.

R. Huddart, A. Santiago-Walker, A. Necchi, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

751P Analysis of circulating tumor DNA (ctDNA) from the phase II BLC2001 trial of erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC) to identify markers of intrinsic resistance to fibroblast growth factor receptor (FGFR)-targeted therapy

R. Huddart, M. Monga, A. Necchi, 2020 .

848PDImpact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase ii checkmate 275 study

Matthew D. Galsky, Alexandre Lambert, C. Horak, 2017 .

A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers.

R. Millikan, Yu Shen, W. Benedict, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer

B. Czerniak, C. Dinney, X. Su, 2016, Oncotarget.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC).

David C. Smith, N. Agarwal, S. Srinivas, 2012 .

Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells

Xifeng Wu, C. Dinney, D. Theodorescu, 2008, Clinical Cancer Research.

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Anthony Patterson, Mark K Buyyounouski, Khurshid A Guru, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors.

C. Dinney, M. Munsell, P. Spiess, 2007, European urology.

Systemic chemotherapy options for metastatic bladder cancer

A. Siefker-Radtke, 2006, Expert review of anticancer therapy.

Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer

B. Czerniak, S. Parikh, C. Dinney, 2017, BJU international.

Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.

R. Millikan, P. Corn, A. Siefker-Radtke, 2015, Clinical Genitourinary Cancer.

Abstract 5368: A phase II study of ipilumimab plus androgen deprivation therapy in castration-sensitive prostate carcinoma

P. Sharma, W. Arap, P. Corn, 2012 .

Clinical Cancer esearch cer Therapy : Clinical Effectiveness of Off-Protocol Adjuvant Chemotherapy for R ients with Urothelial Carcinoma of the Urinary Bladder

R. Millikan, A. Sagalowsky, C. Dinney, 2010 .

Targeting advanced urothelial carcinoma-developing strategies

Jianjun Gao, A. Siefker-Radtke, M. Campbell, 2019, Current opinion in oncology.

Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy.

C. Dinney, S. Matin, A. Kamat, 2011, Urology.

Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma.

B. Czerniak, C. Dinney, S. Matin, 2019, Urologic oncology.

OUTCOMES OF NON-METASTATIC MICROPAPILLARY VARIANT UPPER TRACT UROTHELIAL CARCINOMA

B. Czerniak, C. Dinney, S. Matin, 2019 .

Pilot trial of bone‐targeted therapy with zoledronate, thalidomide, and interferon‐γ for metastatic renal cell carcinoma

K. Do, E. Jonasch, L. Rhines, 2006, Cancer.

Laparoscopy and Robotics Perioperative Outcomes of Laparoscopic Radical Nephroureterectomy and Regional Lymphadenectomy in Patients With Upper Urinary Tract Urothelial Carcinoma After Neoadjuvant Chemotherapy

C. Dinney, S. Matin, A. Kamat, 2011 .

Seminar article Neoadjuvant chemotherapy for bladder cancer

R. Millikan, A. Siefker-Radtke, H. Grossman, 2003 .

Risk group stratification in patients with micropapillary bladder cancer treated with radical cystectomy and/or neoadjuvant chemotherapy.

B. Czerniak, S. Parikh, C. Dinney, 2015 .

Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.

Terry L. Smith, R. Millikan, D. Moore, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases.

B. Czerniak, C. Dinney, A. Kamat, 2018, Human pathology.

757P An observational study of outcomes of patients (pts) with advanced urothelial carcinoma (UC) after anti-programmed death-(Ligand) 1 (PD-[L]1) therapy by fibroblast growth factor receptor gene alteration (FGFRa) status

M. Monga, A. Santiago-Walker, D. Papantoniou, 2020 .

FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.

G. Curigliano, A. Siefker-Radtke, E. Abella, 2019, Journal of Clinical Oncology.

Predictive value of fibroblast growth factor receptor (FGFR) mutations and gene fusions on anti-PD-(L)1 treatment outcomes in patients (pts) with advanced urothelial cancer (UC).

A. Santiago-Walker, K. Patel, A. Siefker-Radtke, 2019, Journal of Clinical Oncology.

Uncommon Cancers of the Bladder

R. Millikan, B. Czerniak, C. Dinney, 2006 .

463: Management of Primary Carcinomas of the Male Urethra

C. Dinney, P. Spiess, A. Kamat, 2006 .

New Settings for Immune Checkpoint Inhibitors in Urothelial Cancer

A. Siefker-Radtke, 2021, Journal of the National Comprehensive Cancer Network.

Phase II study of nivolumab and ipilimumab for advanced bladder cancer of variant histologies (BCVH).

T. Choueiri, G. Sonpavde, G. Bubley, 2019, Journal of Clinical Oncology.

Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience.

Wassim Kassouf, C. Dinney, M. Munsell, 2006, The Journal of urology.

Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.

B. Czerniak, C. Dinney, D. McConkey, 2017, European urology focus.

Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study

E. Plimack, P. Sharma, M. Grimm, 2016 .

Clinical Cancer esearch cer Therapy : Clinical Effectiveness of Off-Protocol Adjuvant Chemotherapy for R ients with Urothelial Carcinoma of the Urinary Bladder

A. Sagalowsky, C. Dinney, S. Shariat, 2010 .

Bladder cancer: narrowing the gap between evidence and practice.

D. Lamm, C. Dinney, B. Bochner, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of Inducible Heat Shock Protein-70 (Hsp72) Enhances Bortezomib-Induced Cell Death in Human Bladder Cancer Cells

C. Dinney, D. McConkey, A. Siefker-Radtke, 2013, PloS one.

A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer

R. Millikan, C. Dinney, Yu Shen, 2013, Cancer.

Abstract CT178: Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275

E. Plimack, M. Galsky, P. Sharma, 2018, Clinical Trials.

NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.

J. Larkin, N. Ibrahim, S. Gettinger, 2018 .

Multimodal kidney‐preserving approach in localised and locally advanced high‐risk upper tract urothelial carcinoma

E. Jonasch, Jianjun Gao, S. Matin, 2021, BJUI compass.

A phase II trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine (IAG), followed by cisplatin, gemcitabine and ifosfamide (CGI) in locally advanced urothelial cancer (UC): Final results from the M.D. Anderson Cancer Center

R. Millikan, C. Dinney, Yu Shen, 2008 .

Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with SMARCB1-deficient kidney malignancies.

G. Genovese, N. Daw, A. Siefker-Radtke, 2019, Journal of Clinical Oncology.

Critical analysis of contemporary clinical research in muscle‐invasive and metastatic urothelial cancer

G. Sonpavde, M. Galsky, J. Rosenberg, 2013, Cancer.

Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the University of Texas M. D. Anderson Cancer Center.

R. Millikan, C. Dinney, S. Matin, 2012 .

Gemcitabine, paclitaxel, and doxorubicin as first-line therapy for patients with advanced urothelial carcinoma and renal insufficiency: A phase II study.

M. Munsell, A. Siefker-Radtke, L. Pagliaro, 2013 .

KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC).

T. Choueiri, G. Sonpavde, D. Bajorin, 2016 .

A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC).

P. Sharma, C. Dinney, Jianjun Gao, 2019, Journal of Clinical Oncology.

AG-013736, a novel VEGF receptor and PDGF receptor inhibitor with potent activity against human bladder carcinoma in vitro and in vivo.

D. McConkey, A. Siefker-Radtke, D. Hu-Lowe, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers.

T. Choueiri, G. Sonpavde, G. Bubley, 2020, Journal of Clinical Oncology.

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

M. Hurwitz, M. Sznol, A. Balar, 2022, Journal for ImmunoTherapy of Cancer.

Emerging Therapies in the Treatment of Bladder Cancer

A. Siefker-Radtke, 2023, Journal of the National Comprehensive Cancer Network.

A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.

P. Thall, E. Jonasch, C. Wood, 2008, The Journal of urology.

Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts).

E. Plimack, P. Sharma, D. Bajorin, 2016 .

KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy.

T. Choueiri, E. Plimack, G. Sonpavde, 2015 .

1521: Variant Histology in Bladder Cancer - Experience in 1246 Patients Undergoing Cystectomy

R. Millikan, C. Dinney, M. Munsell, 2007 .

A phase II randomized four-regimen selection trial incorporating response for sequential chemotherapy in metastatic, unresectable urothelial cancer: Final results from the M. D. Anderson Cancer Center.

R. Millikan, C. Dinney, A. Kamat, 2009, Journal of Clinical Oncology.

Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors

Jianjun Gao, A. Siefker-Radtke, M. Campbell, 2021, JAMA Network Open.

A phase 2 study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations.

J. Burke, B. Mellado, K. Decaestecker, 2016 .

Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience

S. Parikh, C. Dinney, A. Kamat, 2014 .

Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations.

S. Srinivas, E. Yu, A. Siefker-Radtke, 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Phase I/IB trial of sitravatinib (Sitra) + nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC) or other solid malignancies.

Xiaohong Yan, E. Jonasch, Jianjun Gao, 2021 .

A phase II trial to evaluate pemetrexed clinical responses in relation to tumor methylthioadenosine phosphorylase (MTAP) gene status in patients with previously treated metastatic urothelial carcinoma.

B. Czerniak, Jianjun Gao, C. Logothetis, 2019, Journal of Clinical Oncology.

Re: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: Final results

R. Millikan, C. Dinney, Yu Shen, 2013 .

Urachal carcinoma: a pathologic and clinical study of 46 cases.

B. Czerniak, C. Dinney, A. Kamat, 2015, Human pathology.

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer

Mauro A. A. Castro, J. Weinstein, K. Hoadley, 2019, European urology.

Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).

R. Huddart, S. Park, J. Ku, 2023, Journal of Clinical Oncology.